{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:23:46Z","timestamp":1790504626432,"version":"4.1.0"},"reference-count":78,"publisher":"Impact Journals, LLC","issue":"49","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,6,26]]},"DOI":"10.18632\/oncotarget.25670","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T18:34:59Z","timestamp":1530038099000},"page":"29193-29207","source":"Crossref","is-referenced-by-count":46,"title":["BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition"],"prefix":"10.18632","volume":"9","author":[{"given":"Sa Rang","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia M.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit M.","family":"Cyrenne","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick F.","family":"Monico","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima N.","family":"Mirza","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kacie R.","family":"Carlson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine M.","family":"Foss","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Girardi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2018,6,26]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI24826","article-title":"Immunopathogenesis and therapy of cutaneous T cell lymphoma","volume":"115","author":"Rook","year":"2005","journal-title":"J Clin Invest"},{"key":"2","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1056\/NEJMra032810","article-title":"The pathogenesis of mycosis fungoides","volume":"350","author":"Wilson","year":"2004","journal-title":"N Engl J Med"},{"key":"3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1468-3083.2004.00937.x","article-title":"Clinicopathological spectrum of mycosis fungoides","volume":"18","author":"Kempf","year":"2004","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/ajh.23756","article-title":"Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management","volume":"89","author":"Wilcox","year":"2014","journal-title":"Am J Hematol"},{"key":"5","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous T cell lymphomas","volume":"105","author":"Kempf","year":"2005","journal-title":"Blood"},{"key":"6","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.V97.3.624","article-title":"Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma","volume":"97","author":"Russell-Jones","year":"2001","journal-title":"Blood"},{"key":"7","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Dean","year":"2010","journal-title":"J Clin Oncol"},{"key":"8","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-12-3488","article-title":"TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T cell lymphoma","volume":"19","author":"Clark","year":"2013","journal-title":"Clin Cancer Res"},{"key":"9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12185-017-2245-x","article-title":"Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS)","volume":"106","author":"Ozcan","year":"2017","journal-title":"Int J Hematol"},{"key":"10","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1080\/10428194.2017.1347650","article-title":"Current systemic therapeutic options for advanced mycosis fungoides and S\u00e9zary syndrome","volume":"59","author":"Abdulla","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"11","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-15-1435","article-title":"Romidepsin and azacitidine synergize in their epigenetic modulatory effects to induce apoptosis in CTCL","volume":"22","author":"Dummer","year":"2016","journal-title":"Clin Cancer Res"},{"key":"12","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Liu","year":"2015","journal-title":"Nat Genet"},{"key":"13","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/ng.3370","article-title":"Genomic analysis of mycosis fungoides and S\u00e9zary syndrome identifies recurrent alterations in TNFR2","volume":"47","author":"Tavallaee","year":"2015","journal-title":"Nat Genet"},{"key":"14","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and S\u00e9zary syndrome","volume":"47","author":"Palomero","year":"2015","journal-title":"Nat Genet"},{"key":"15","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ng.3444","article-title":"Genomic profiling of S\u00e9zary syndrome identifies alterations of key T cell signaling and differentiation genes","volume":"47","author":"Muzny","year":"2015","journal-title":"Nat Genet"},{"key":"16","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/blood-2014-11-611194","article-title":"Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides","volume":"126","author":"Eischen","year":"2015","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1158\/1078-0432.CCR-14-3322","article-title":"The use of transcriptional profiling to improve personalized diagnosis and management of cutaneous T-cell lymphoma (CTCL)","volume":"21","author":"Kupper","year":"2015","journal-title":"Clin Cancer Res"},{"key":"18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1042\/BJ20050465","article-title":"STAT3-mediated transcription of Bcl-2, Mcl-1, and c-IAP2 prevents apoptosis in polyamine-depleted cells","volume":"392","author":"Johnson","year":"2005","journal-title":"Biochem J"},{"key":"19","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/mgg3.121","article-title":"Personalized treatment of S\u00e9zary syndrome by targeting a novel CTLA4:CD28 fusion","volume":"3","author":"Trent","year":"2015","journal-title":"Mol Genet Genomic Med"},{"key":"20","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00277-006-0127-z","article-title":"Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomas","volume":"85","author":"Lee","year":"2006","journal-title":"Ann Hematol"},{"key":"21","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/sj.leu.2401415","article-title":"Inhibition of constitutively activated Stat3 correlates with altered Bcl-2\/Bax expression and induction of apoptosis in mycosis fungoides tumor cells","volume":"13","author":"Odum","year":"1999","journal-title":"Leukemia"},{"key":"22","doi-asserted-by":"publisher","first-page":"45730","DOI":"10.18632\/oncotarget.10160","article-title":"STAT5 induces miR-21 expression in cutaneous T cell lymphoma","volume":"7","author":"Krejsgaard","year":"2016","journal-title":"Oncotarget"},{"key":"23","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Jin","year":"2013","journal-title":"Nat Med"},{"key":"24","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1182\/blood-2017-06-792150","article-title":"Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T cell-lymphoma patients","volume":"130","author":"Girardi","year":"2017","journal-title":"Blood"},{"key":"25","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","article-title":"BET inhibitors: a novel epigenetic approach","volume":"28","author":"LoRusso","year":"2017","journal-title":"Ann Oncol"},{"key":"26","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1128\/MCB.14.2.1039","article-title":"Differential regulation of the c-myc oncogene promoter by the NF-kappa B rel family of transcription factors","volume":"14","author":"Sonenshein","year":"1994","journal-title":"Mol Cell Biol"},{"key":"27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11864-016-0410-8","article-title":"Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside","volume":"17","author":"Choi","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4161\/trns.22542","article-title":"Two faces of brd4: mitotic bookmark and transcriptional lynchpin","volume":"4","author":"Singer","year":"2013","journal-title":"Transcription"},{"key":"29","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.molcel.2005.06.029","article-title":"Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4","volume":"19","author":"Zhou","year":"2005","journal-title":"Mol Cell"},{"key":"30","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"McKeown","year":"2010","journal-title":"Nature"},{"key":"31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"key":"32","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Chicas","year":"2011","journal-title":"Nature"},{"key":"33","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"McKeown","year":"2011","journal-title":"Cell"},{"key":"34","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1182\/blood-2012-02-413021","article-title":"BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia","volume":"120","author":"Weinstock","year":"2012","journal-title":"Blood"},{"key":"35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1541-7786.MCR-16-0221","article-title":"Exploitation of castration-resistant prostate cancer transcription factor dependencies by the novel BET inhibitor ABBV-075","volume":"15","author":"Shen","year":"2017","journal-title":"Mol Cancer Res"},{"key":"36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00403-017-1749-9","article-title":"BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines","volume":"309","author":"Sato","year":"2017","journal-title":"Arch Dermatol Res"},{"key":"37","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staining and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Ranki","year":"2007","journal-title":"Blood"},{"key":"38","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaad.2015.12.018","article-title":"Cutaneous T-cell lymphoma (CTCL): current practices in blood assessment and the utility of T-cell receptor (TCR)-V\u03b2 chain restriction","volume":"74","author":"Girardi","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"39","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrm2858","article-title":"Genomic instability\u2014an evolving hallmark of cancer","volume":"11","author":"Halazonetis","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"40","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jid.2016.10.037","article-title":"FISH panel for leukemic CTCl","volume":"137","author":"Girardi","year":"2017","journal-title":"J Invest Dermatol"},{"key":"41","doi-asserted-by":"publisher","first-page":"95981","DOI":"10.18632\/oncotarget.21619","article-title":"Analysis of CTCL cell lines reveals important differences between mycosis fungoides\/S\u00e9zary syndrome vs. HTLV-1+ leukemic cell lines","volume":"8","author":"Litvinov","year":"2017","journal-title":"Oncotarget"},{"key":"42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12154-009-0029-3","article-title":"Hill coefficients, dose-response curves and allosteric mechanisms","volume":"3","author":"Prinz","year":"2010","journal-title":"J Chem Biol"},{"key":"43","doi-asserted-by":"crossref","first-page":"8369","DOI":"10.1021\/acs.jmedchem.7b00746","article-title":"Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075\/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor","volume":"60","author":"Li","year":"2017","journal-title":"J Med Chem"},{"key":"44","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1021\/jm401088k","article-title":"Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of BET bromodomains","volume":"56","author":"Jeffrey","year":"2013","journal-title":"J Med Chem"},{"key":"45","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1021\/acs.jmedchem.5b01882","article-title":"Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials","volume":"59","author":"Cummings","year":"2016","journal-title":"J Med Chem"},{"key":"46","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"47","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol Rev"},{"key":"48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4161\/spmg.19885","article-title":"Cell lines","volume":"2","author":"Dufour","year":"2012","journal-title":"Spermatogenesis"},{"key":"49","doi-asserted-by":"publisher","first-page":"86312","DOI":"10.18632\/oncotarget.21146","article-title":"JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"key":"50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-017-0434-3","article-title":"Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines","volume":"10","author":"Hoffmann","year":"2018","journal-title":"Clin Epigenetics"},{"key":"51","doi-asserted-by":"publisher","first-page":"21507","DOI":"10.18632\/oncotarget.4242","article-title":"Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling","volume":"6","author":"McArthur","year":"2015","journal-title":"Oncotarget"},{"key":"52","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/ijc.29269","article-title":"Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma","volume":"136","author":"Koeffler","year":"2015","journal-title":"Int J Cancer"},{"key":"53","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood-2015-04-639542","article-title":"Synergistic activity of BET protein antagonist-based combination in mantle cell lymphoma cells sensitive or resistant ibrutinib","volume":"126","author":"Krieger","year":"2015","journal-title":"Blood"},{"key":"54","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/1535-7163.MCT-15-0924","article-title":"BET inhibition induces apoptosis in aggressive B-cell lymphoma via epigenetic regulation of BCL-2 family members","volume":"15","author":"Johnstone","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"55","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.molcel.2011.10.001","article-title":"A unified model of mammalian BCL-2 protein family interactions at the mitochondria","volume":"44","author":"Green","year":"2011","journal-title":"Mol Cell"},{"key":"56","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Sims","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"57","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Young","year":"2013","journal-title":"Cell"},{"key":"58","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Lugo","year":"2011","journal-title":"Nature"},{"key":"59","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.18632\/oncotarget.1534","article-title":"BET bromodomain protein inhibition is a therapeutic option for medulloblastoma","volume":"4","author":"Eggert","year":"2013","journal-title":"Oncotarget"},{"key":"60","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/nm.3952","article-title":"Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma","volume":"21","author":"Heid","year":"2015","journal-title":"Nat Med"},{"key":"61","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-15-1335","article-title":"Clinical response of carcinomas harboring the BRD4-NUT oncoprotein to the targeted bromodomain inhibitor OTX015\/MK-8628","volume":"6","author":"French","year":"2016","journal-title":"Cancer Discov"},{"key":"62","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1182\/blood.V126.23.1491.1491","article-title":"BET inhibitor CPI-0610 is well tolerated and induces responses in diffuse large B-cell lymphoma and follicular lymphoma: preliminary analysis of an ongoing phase 1 study","volume":"126","author":"Younes","year":"2015","journal-title":"Blood"},{"key":"63","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.cell.2012.02.013","article-title":"Histone recognition and large-scale structural analysis of the human bromodomain family","volume":"149","author":"Knapp","year":"2012","journal-title":"Cell"},{"key":"64","doi-asserted-by":"crossref","first-page":"E2721","DOI":"10.1073\/pnas.1406722111","article-title":"BET and HDAC inhibitors induce similar genes and biological effects and synergize to skill in Myc-induced murine lymphoma","volume":"111","author":"Nilsson","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"65","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1038\/bcj.2013.24","article-title":"BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia","volume":"3","author":"Knapp","year":"2013","journal-title":"Blood Cancer J"},{"key":"66","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1535-7163.MCT-13-0770","article-title":"Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells","volume":"13","author":"Qi","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"67","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.celrep.2015.10.013","article-title":"Histone deacetylases positively regulate transcription through the elongation machinery","volume":"13","author":"Kim","year":"2015","journal-title":"Cell Rep"},{"key":"68","first-page":"2470","article-title":"Histone deacetylase inhibitors mimic BET inhibitors and cause RNA polymerase pausing at MYC, KIT, and other oncogenes in t(8;21) AML","volume":"130","author":"Hiebert","year":"2017","journal-title":"Blood"},{"key":"69","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1158\/1078-0432.CCR-15-2389","article-title":"Molecular Pathways: Targeting the PI3K pathway in cancer-BET inhibitors to the rescue","volume":"22","author":"Parsons","year":"2016","journal-title":"Clin Cancer Res"},{"key":"70","first-page":"4","article-title":"Bromodomain inhibition in diffuse large B-cell lymphoma\u2014giving MYC a brake","volume":"21","author":"Gascoyne","year":"2016","journal-title":"Clin Cancer Res"},{"key":"71","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1158\/1535-7163.MCT-16-0459","article-title":"Vulnerability of small-cell lung cancer to apoptosis induced by the combination of BET bromodomain proteins and BCL2 inhibitor","volume":"16","author":"Kati","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"72","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1038\/s41388-017-0111-1","article-title":"The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1\/A1 inandmodels of MYC+\/BCL2+ double hit lymphoma","volume":"37","author":"Lopez-Guillermo","year":"2018","journal-title":"Oncogene"},{"key":"73","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1128\/MCB.01481-08","article-title":"Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1","volume":"29","author":"Grant","year":"2009","journal-title":"Mol Cell Biol"},{"key":"74","first-page":"161","article-title":"Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides","volume":"28A","author":"Thestrup-Pedersen","year":"1992","journal-title":"Cell Dev Biol"},{"key":"75","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/ijc.2910490218","article-title":"Establishment of an IL-2 independent, human T-cell line possessing only the p70 IL-2 receptor","volume":"49","author":"Ruscetti","year":"1991","journal-title":"Int J Cancer"},{"key":"76","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood.V55.3.409.409","article-title":"Mitogen requirements for thepropagation of cutaneous T-cell lymphomas","volume":"55","author":"Guccion","year":"1980","journal-title":"Blood"},{"key":"77","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/1523-1747.ep12514693","article-title":"A clonal CD4-positive T-cell line established from the blood of a patient with Sezary syndrome","volume":"96","author":"DeFreitas","year":"1991","journal-title":"J Invest Dermatol"},{"key":"78","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/jid.2011.254","article-title":"Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients","volume":"132","author":"Mane","year":"2012","journal-title":"J Invest Dermatol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25670","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T18:50:27Z","timestamp":1589050227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,26]]},"references-count":78,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2018,6,26]]}},"alternative-id":["25670","30018745"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.25670","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,26]]}}}